Progyny, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Progyny, Inc. (PGNY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $335.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-02-27
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-12-31 was $800.00K, a 33.33% increase year-over-year.
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-09-30 was $649.00K, a 13.66% increase year-over-year.
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-12-31 was $600.00K.
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-09-30 was $571.00K.
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $335.20M, a 65.61% increase from fiscal 2024.
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $202.40M, a 50.93% increase from fiscal 2023.
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $134.10M, a 114.22% increase from fiscal 2022.
- Progyny, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $62.60M, a 291.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $335.20M 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $202.40M 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $134.10M 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $62.60M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $16.00M 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $9.30M 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.45M derived: sum of 2 quarters · filed 2022-03-01 | $2.80M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $649.00K 10-Q · filed 2019-12-06 | $2.00M 10-Q · filed 2019-12-06 | ||
| 2018-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.17M derived: sum of 2 quarters · filed 2021-03-01 | $3.70M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $571.00K 10-Q · filed 2019-12-06 | $3.10M 10-Q · filed 2019-12-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |